Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Akeso clinical trials
The registry lists 165 studies whose lead sponsor is Akeso or one of 1 company grouped under it. 67 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.
Keep track of what changes. Save the Akeso studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Akeso.
- Akeso156 studiesSame company
Something wrong?
- Akesobio Australia Pty Ltd9 studies →Regional office
Something wrong?
Focus areas
Conditions Akeso leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 165. Browse all 165 →
- A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.Not yet recruitingNCT07883213Phase 2
- A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous UrticariaNot yet recruitingNCT07875426Phase 2
- A Study of AK157D1 for Injection in Advanced Solid TumorsRecruitingNCT07847281Phase 1
- Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaRecruitingNCT07700979Phase 3
- A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal PolypsNot yet recruitingNCT07755371Phase 2
- A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung CancerRecruitingNCT07623356Phase 1/2
- A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast CancerRecruitingNCT07591090Phase 2
- A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung CancerRecruitingNCT07669779Phase 2
- A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial CarcinomaNot yet recruitingNCT07636772Phase 2
- A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male ParticipationsNot yet recruitingNCT07619001Phase 1
- A Phase I Clinical Study of AK150 in Advanced Malignant Solid TumorNot yet recruitingNCT07566247Phase 1
- A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast CancerNot yet recruitingNCT07560124Phase 1/2
- A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)RecruitingNCT07547787
- Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon CancerRecruitingNCT07412613Phase 3
- Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung CancerRecruitingNCT06928389Phase 3
- A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic DermatitisNot yet recruitingNCT07502222Phase 2
- Study of AK119 Combined With AK112 in Patients With Advanced Solid TumorsRecruitingNCT05689853Phase 1/2
- AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast CancerRecruitingNCT06767527Phase 3
- A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.RecruitingNCT07052253Phase 2
- A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation TherapyRecruitingNCT07010263Phase 3
- A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)RecruitingNCT06530251Phase 1/2
- AK112 and Chemotherapy in First-line Metastatic Colorectal CancerRecruitingNCT06951503Phase 3
- A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerRecruitingNCT06953999Phase 3
- A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07449780Phase 3
- A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract CancerRecruitingNCT06938321Phase 1/2
- A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic CancerRecruitingNCT07114315Phase 2
- A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic RhinitisNot yet recruitingNCT07436234Phase 2
- A Study to Evaluate the Efficacy and Safety of AK139 in Participants With AsthmaNot yet recruitingNCT07436221Phase 2
- A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ AdenocarcinomaRecruitingNCT07023315Phase 3
- A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver MetastasesNot yet recruitingNCT07357220Phase 1/2
- Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)RecruitingNCT07263919Phase 2
- A Clinical Trial of AK152 in Healthy Volunteers and Patients With Alzheimer' s DiseaseNot yet recruitingNCT07301502Phase 1
- A Study of AK138D1 in Advanced Malignant TumorsRecruitingNCT07281326Phase 1
- A Study of Ivonescimab in First-Line ES-SCLCRecruitingNCT07245446Phase 2
- A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaRecruitingNCT04982276Phase 1/2
- AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) TreatmentNot yet recruitingNCT07158840Phase 2
- A Study of AK146D1 for Injection in Advanced Solid TumorsRecruitingNCT07067567Phase 1
- A Study of AK146D1 for Injection in the Treatment of Advanced Solid TumorsRecruitingNCT06929663Phase 1
- AK129 Combination Therapy for Advanced Solid TumorsRecruitingNCT06943820Phase 1/2
- A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCCNot yet recruitingNCT06984718Phase 2
- A Clinical Study of AK139 in Healthy SubjectsNot yet recruitingNCT06947109Phase 1
- Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian CancerRecruitingNCT06686030Phase 2
- A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDACNot yet recruitingNCT06913218Phase 1
- An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian CancerRecruitingNCT06560112Phase 2
- A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative ResectionRecruitingNCT05489289Phase 3
- A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular CarcinomaRecruitingNCT06371157Phase 3
- A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCRecruitingNCT06617416Phase 3
- A Study of AK109 Combined With AK104 in Patients With Advanced Solid TumorsRecruitingNCT05142423Phase 1/2
- A Phase I Study of AK138D1 in the Treatment of Advanced Solid TumorsRecruitingNCT06730386Phase 1
- AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)Not yet recruitingNCT06860789Phase 1